Pennell P B, Ogaily M S, Macdonald R L
Department of Neurology, University of Michigan Medical Center, Ann Arbor.
Neurology. 1995 Mar;45(3 Pt 1):456-60. doi: 10.1212/wnl.45.3.456.
A 53-year-old woman began taking felbamate for uncontrolled complex partial seizures. Four months later, she developed fatigue and ecchymotic skin lesions. Laboratory studies revealed very severe aplastic anemia. There have been an additional nine reported cases of aplastic anemia in the setting of felbamate treatment. The association between felbamate and aplastic anemia has resulted in a joint recommendation by the US Food and Drug Administration and the manufacturer of felbamate, Carter-Wallace, Inc., for the immediate withdrawal of patients from treatment with felbamate.
一名53岁女性开始服用非氨酯以控制复杂性部分性癫痫发作，但病情仍未得到控制。四个月后，她出现疲劳和皮肤瘀斑。实验室检查显示为非常严重的再生障碍性贫血。在非氨酯治疗过程中，另外还有9例再生障碍性贫血的报告病例。非氨酯与再生障碍性贫血之间的关联已导致美国食品药品监督管理局和非氨酯制造商卡特-华莱士公司联合建议立即停止使用非氨酯治疗的患者。
